Publikationen - neuroendokrine pankreastumore

Direkt zum Seiteninhalt

Hauptmenü:

Publikationen

C-reactive protein as a new prognostic factor for survival in patients with pancreatic neuroendocrine neoplasia.
Wiese D, Kampe K, Waldmann J, Heverhagen AE, Bartsch DK, Fendrich V.
J Clin Endocrinol Metab, 101:937-44 (2016)

ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M,
Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT; Vienna Consensus Conference participants.
Neuroendocrinology 103:153-71 (2016)

Minimally invasive versus open pancreatic surgery in patients with multiple endocrine neoplasia type 1.
Lopez CL, Albers MB, Bollmann C, Manoharan J, Waldmann J, Fendrich V, Bartsch DK.
World J Surg; 40:1729-36.(2016)


Controversies in surgery for multiple endocrine neoplasia type 1-associated Zollinger- Ellison syndrome.
Bartsch DK, Albers MB.
International Journal of Endocrine Oncology 4: 263-371 (2015)

Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.

Bartsch DK, Slater EP, Albers M, Knoop R, Chaloupka B, Lopez CL, Fendrich V, Kann PH, Waldmann J.
J Clin Endocrinol Metab. 2014 Nov; 99(11):E2387-91.

Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases.

Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, Tamburrino D. Keck T, Caplin ME, Bartsch DK, Thirlwell C, Fusai G, Falconi M.
Neuroendocrinology 102:68-76 (2015)

IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells.

Münzberg C, Höhn K, Krndija D, Maaß U, Bartsch DK, Slater EP, Oswald F, Walther P, Seufferlein T, von Wichert G.
J Cell Mol Med 19:948-959 (2015)

Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas.

Lichtenauer UD, Di Dalmazi G, Slater EP, Wieland T, Kuebart A, Schmittfull A, Schwarzmayr T, Diener S, Wiese D, Thasler WE, Reincke M, Meitinger T, Schott M, Fassnacht M, Bartsch DK, Strom TM, Beuschlein F.
J Clin Endocrinol Metab 100:E776-782. (2015)

EndoplasmicReticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.

Klieser E, Illig R, Státtner S, Primavesi F, Jáger T, Swierczynski S, Kiesslich T, Kemmerling R, Bollmann C, Di Fazio P, Neureiter D.
Anticancer Res 35:6127-6136 (2015)

Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.

Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch DK, Ocker M, Quint K,Heverhagen AE.
J Surg Res 194:388-393 (2015)

CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms

Krug S, Kühnemuth B, Griesmann H, Neesse A, Mühlberg L, Boch M, Kortenhaus J, Fendrich V, Wiese D, Sipos B, Friemel J, Gress TM, Michl P.
Endocr Relat Cancer. 2014 Dec; 21(6): 879-90.

Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.

Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch DK, Ocker M, Quint K, Heverhagen AE.
J Surg Res. 2014 Nov 5. pii: S0022-4804(14)00982-2

Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections.

Dieckhoff P, Runkel H, Daniel H, Wiese D, Koenig A, Fendrich V, Bartsch DK, Moll R, Müller D, Arnold R, Gress T, Rinke A.
Digestion. 2014; 90(2):89-97

Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?
Bartsch DK, Dietzel K, Bargello M, Matthaei E, Kloeppel G, Esposito I, Heverhagen JT, Gress TM, Slater EP, Langer P.
Fam Cancer. 2013 Mar;12(1):89-96.

Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.

Fendrich V, Sparn M, Lauth M, Knoop R, Plassmeier L, Bartsch DK, Waldmann J.
Pancreatology. 2013 Sep-Oct;13(5):502-7. Epub 2013 Aug 20.

Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.

Plassmeier L, Knoop R, Waldmann J, Kesselring R, Buchholz M, Fichtner-Feigl S, Bartsch DK, Fendrich V.
Langenbecks Arch Surg. 2013 Oct;398(7):989-96. Epub 2013 Aug 30.

Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).

Fensterer H, Schade-Brittinger C, Müller HH, Tebbe S, Fass J, Lindig U, Settmacher U, Schmidt WE, Märten A, Ebert MP, Kornmann M, Hofheinz R, Endlicher E, Brendel C, Barth PJ, Bartsch DK, Michl P, Gress TM; Arbeitsgemeinschaft Internistische Onkologie.
Ann Oncol. 2013 Oct;24(10):2576-81. Epub 2013 Jul 29.

Embryonic Transcription Factors CDX2 and Oct4 Are Overexpressed in Neuroendocrine Tumors of the Ileum: A Pilot Study.

Heverhagen AE, Geis C, Fendrich V, Ramaswamy A, Montalbano R, Di Fazio P, Bartsch DK, Ocker M, Quint K.
Eur Surg Res. 2013 Jul 23;51(1-2):14-20.

Shortness: an unknown phenotype of multiple endocrine neoplasia type 1.

López CL, Langer P, Waldmann J, Fendrich V, Sitter H, Nies C, Bartsch DK.
Eur J Endocrinol. 2013 Jul;169(1):133-7.

Outcome of surgery for ileojejunal neuroendocrine tumors.
Habbe N, Fendrich V, Heverhagen A, Ramaswamy A, Bartsch DK.
Surg Today. 2013 Oct;43(10):1168-74.Epub 2012 Nov 11.

Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
Fendrich V, Maschuw K, Rehm J, Buchholz M, Holler JP, Slater EP, Bartsch DK, Waldmann J.
ScientificWorldJournal. 2012;2012:529151. Epub 2012 Dec 27.

Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems.

Capurso G, Fendrich V, Rinzivillo M, Panzuto F, Bartsch DK, Delle Fave G.
Int J Mol Sci. 2012 Dec 20;14(1):30-45.

Impact of lymphadenectomy on survival in patients with sporadic gastrinoma.

Bartsch DK, Waldmann J, Fendrich V, Boninsegna L, Lopez CL, Partelli S, Falconi M.
Br J Surg. 2012 Sep; 99(9):1234-40

Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive System: well-differentiated pancreatic non-functioning tumors.

Falconi M, Bartsch DK, Eriksson b, Klöppel G, Lopes JM, O’Connor JM, Salazar R, Taal BG, Vullierme MP, O’Toole D;
Neuroendocrinology, 2012, 95(2):120-34

Successful selective internal radiotherapy SIRT) in a patient with a malignant solid pseudopapillary pancreatic neoplasm (SPN).
Krug S, Bartsch DK, Schober M, Librizzi D, Pfestroff A, Burbelko M, Moll R, Michl P, Gress TM.
Pancreatology. 2012, 12(5):423-7

Peripheral bone mineral density in correlation to disease-related predisposing conditions in patients with multiple endocrine neoplasia type 1.
Kann PH, Bartsch DK, Langer P, Waldmann J, Hadji P, Pfützner A, Klüsener J.
J Endocrinol Invest. 2012, 35:573-9

Epithelial-Mesenchymal Transition is a critical step in tumorgenesis of pancreatic neuroendocrine tumors.
Fendrich V, Maschuw K, Waldmann J, Buchholz M, Rehm J, Gress T.M, Bartsch D.K, König A.
Cancers 2012, 4, 281-294

Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.

Fendrich V, Maschuw K, Rehm J, Buchholz M, Holler JP, Slater EP, Bartsch DK, Waldmann J.
The Scientific World Journal 2012, 2012:529151

Partial pancreaticoduodenetomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1.

Lopez CL, Falconi M, Waldmann J, Boninsegna L, Fendrich V, Goretzki PK, Langer P, Kann PH, Partelli S, Bartsch DK.
Ann Surg, 2012, 257(2):308-14


 

   Prof. Dr. med. D.K. Bartsch


 
 
 
 
Zurück zum Seiteninhalt | Zurück zum Hauptmenü